The eight participants who indicated that they wanted to quit wit

The eight participants who indicated that they wanted to quit within 6 months, including four who intended to quit within 30 days, were classified as Olaparib clinical intention positive. We found no significant differences between the groups on any demographic or smoking history measure (Table 1). No participant missed more than one pill in the week prior to each session. Table 1. Demographic and smoking characteristics of study participants Smoking behavior between sessions There were no main effects of intention or condition, and no intention �� condition interaction, on CO level measured upon arrival for sessions (see Table 1). We found a significant effect of condition on average daily smoking rate in the week prior to each session, F(2, 46) = 12.47, p < .

001, with post-hoc tests indicating that smoking rates were higher in the week prior to Session 1 than in subsequent weeks (p < .01). We found no indication that bupropion reduced daily smoking rate and no main effect of intention or intention �� condition interaction on daily smoking rate. The intention-negative group smoked 22.5 cigarettes/day (SD = 10.9), 19.0 cigarettes/day (SD = 11.5), and 18.7 cigarettes/day (SD = 11.3) in the weeks before the nonabstinent, abstinent plus placebo, and abstinent plus bupropion sessions, respectively. The corresponding rates for the intention-positive group were 24.3 (SD = 11.5), 19.4 (SD = 14.4), and 19.6 (SD = 12.0). Nicotine withdrawal symptoms and smoking urge levels We found a main effect of condition on precue breath CO level, F(2, 46) = 27.87, p < .

001, with post-hoc tests indicating that abstinence significantly reduced CO levels (p < .001). There was no main effect of intention or intention �� condition interaction on precue CO level. For the intention-negative group, precue breath CO levels in the nonabstinent, abstinent plus placebo, and abstinent plus bupropion conditions were 20.8 ppm (SD = 7.2), 10.5 ppm (SD = 6.1), and 10.9 ppm (SD = 5.7), respectively. The corresponding values for the intention-positive group were 19.5 ppm (SD = 10.1), 10.3 ppm (SD = 3.8), and 10.5 ppm (SD = 5.6). We found a marginal effect of condition on precue MNWS score, F(2, 46) = 2.95, p = .06; ��2 = .11. Means indicated that abstinence tended to increase MNWS score, but bupropion did not reduce this effect. We found no main effect of intention or intention �� condition interaction on MNWS score (��2 �� .

05). For the intention-negative group, MNWS scores in the nonabstinent, abstinent plus placebo, and abstinent plus bupropion conditions were 12.5 (SD = 18.8), 19.9 (SD = 22.9), and 21.4 (SD = 24.8), respectively. The corresponding MNWS scores for the intention-positive group were 7.8 (SD Carfilzomib = 8.6), 10.6 (SD = 9.3), and 11.6 (SD = 10.9). We found significant main effects of cue and condition on urge score, F(1, 23) = 25.98, p < .001, and F(2, 46) = 4.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>